- Details
- Description
-
Packaging Size1Bottle/Box
-
Strength200mg/Bottle
-
CompositonSacituzumab Tirumotecan
-
TreatmentTriple-Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC)
-
FormInjection
-
Brand佳泰莱（Jiataile）
-
Quantity Unit200mg*1Bottle/Box
-
ManufacturerKELUN-BIOTECH,China
About Sacituzumab tirumotecan
Sacituzumab tirumotecan, also known as sac-TMT, SKB264, or MK-2870, is an antibody-drug conjugate (ADC) being studied for various cancers, particularly non-small cell lung cancer (NSCLC) and breast cancer. It works by targeting and delivering a cytotoxic payload to cancer cells expressing the TROP2 protein.
TROP2, a tumor-associated antigen expressed on many epithelial-derived tumors.The ADC binds to TROP2 on cancer cells, then releases a cytotoxic payload (an undisclosed topoisomerase I inhibitor) that inhibits tumor cell proliferation and causes cell death. Utilizes a unique Kthiol linker to attach the payload to the antibody, ensuring efficient delivery and release.
Applications and Studies:
Triple-Negative Breast Cancer (TNBC): Studies have shown a significant survival benefit in pretreated patients with advanced TNBC compared to chemotherapy.
《Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC》
Non-Small Cell Lung Cancer (NSCLC): Investigated in patients with advanced, previously treated NSCLC, including those with EGFR mutations.
《China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC》
Other Cancers:Clinical trials are underway exploring the use of sacituzumab tirumotecan in other cancers, such as gastric cancer and endometrial cancer.
